Atezolizumab,Cabozantinib
Roche
['contact-3', 'atezo', 'kidney cancer']
kicking off the kidney cancer session the one and only with the results of the contact-3 trial showing no significant benefit of adding atezolizumab to cabozanitonib after prior ici. #asco23 this negative trial addresses an important question that may have 
PGY-2 @BrighamMedRes | @USJLiban MSc '16 MD '18 | @DanaFarber Research '21 | @ASCO #IMG CoP & #JCOCCI Editorial Board | Cancer Genomics |
FCOI: https://t.co/dYsEwGGqP1